20.5 USD
-0.17 (-0.82%)
20.64 USD
+0.14 (+0.68%)
Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 190 industry peers in the Pharmaceuticals industry. PCRX has an excellent profitability rating, but there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
- PCRX had positive earnings in the past year.
- PCRX had a positive operating cash flow in the past year.
- PCRX had positive earnings in 4 of the past 5 years.
- PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 1.65%, PCRX belongs to the top of the industry, outperforming 81.05% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 2.95%, PCRX belongs to the top of the industry, outperforming 82.11% of the companies in the same industry.
- PCRX has a better Return On Invested Capital (3.63%) than 81.58% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 12.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- PCRX has a better Profit Margin (2.99%) than 79.47% of its industry peers.
- With an excellent Operating Margin value of 8.88%, PCRX belongs to the best of the industry, outperforming 81.05% of the companies in the same industry.
- In the last couple of years the Operating Margin of PCRX has grown nicely.
- Looking at the Gross Margin, with a value of 79.17%, PCRX belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
- In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
- Compared to 1 year ago, PCRX has less shares outstanding
- PCRX has more shares outstanding than it did 5 years ago.
- PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
- PCRX has an Altman-Z score of 1.85. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- PCRX has a Altman-Z score (1.85) which is comparable to the rest of the industry.
- The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
- PCRX has a better Debt to FCF ratio (3.03) than 90.53% of its industry peers.
- A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
- PCRX has a Debt to Equity ratio of 0.52. This is in the lower half of the industry: PCRX underperforms 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.85 |
ROIC/WACC0.46
WACC7.83%
2.3 Liquidity
- PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 5.26, PCRX is in the better half of the industry, outperforming 64.74% of the companies in the same industry.
- A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.78, PCRX perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- The earnings per share for PCRX have decreased by -6.90% in the last year.
- The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
- The Revenue for PCRX has decreased by -16.85% in the past year. This is quite bad
- The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- The Earnings Per Share is expected to grow by 7.01% on average over the next years.
- Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.38% on average per year.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 6.90, the valuation of PCRX can be described as very cheap.
- 93.68% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 27.25, PCRX is valued rather cheaply.
- The Price/Forward Earnings ratio is 5.90, which indicates a rather cheap valuation of PCRX.
- Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 93.16% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 25.98. PCRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.9 | ||
| Fwd PE | 5.9 |
4.2 Price Multiples
- PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 96.32% of the companies in the same industry.
- 96.32% of the companies in the same industry are more expensive than PCRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.1 | ||
| EV/EBITDA | 5.91 |
4.3 Compensation for Growth
- PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.49
EPS Next 2Y4.05%
EPS Next 3Y6.92%
5. Dividend
5.1 Amount
- No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 6.9 and the Price/Book (PB) ratio is 1.21.